Lukas C. Amler

PCR Oncology — United States

Medicine · Health Sciences

53h-index13.8kcitations291works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(71), HER2/EGFR in Cancer Research(58), Cancer Genomics and Diagnostics(57), Monoclonal and Polyclonal Antibodies Research(37), Melanoma and MAPK Pathways(36)

Publications291 total

Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Data from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Data from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Data from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2023Open Access
Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Supplementary Figures 1-7, Methods from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2023Open Access
Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Data from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2023Open Access
Supplementary Figures 1-7, Methods from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2023Open Access
Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Figure S3E from Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
2023Open Access
Supplementary Methods from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
2023Open Access
Figure S3D from Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
2023Open Access
Data from Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer
2023Open Access
Supplementary Methods, Figures 1-9, Tables 1-4 from DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
2023Open Access
Data from DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
2023Open Access
Figure S3A from Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
2023Open Access
Figure S2 from Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
2023Open Access
Supplementary Figures 1-2 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
2023Open Access
Data from Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Mark R. Lackner(18), Garret M. Hampton(13), Carol O’Brien(10), David S. Shames(8), Elizabeth A. Punnoose(7), Jill M. Spoerke(7), Thomas Januario(6), Guy Cavet(6), Robert L. Yauch(6), Zora Modrušan(6), Heidi Savage(6), Howard M. Stern(6), Somasekar Seshagiri(5), Andrea Pirzkall(5), Richard Bourgon(5), Manfred Schwab(5), Marcin Kowanetz(4), Wei Zou(4), Ling Huw(4), Zachary Boyd(4)